GM-CSF and IL-4 Induce Dendritic Cell Differentiation and Disrupt Osteoclastogenesis Through M-CSF Receptor Shedding by Up-regulation of TNF-alpha Converting Enzyme (TACE)
Overview
Authors
Affiliations
Monocytes give rise to macrophages, osteoclasts (OCs), and dendritic cells (DCs). Macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kappaB (RANK) ligand induce OC differentiation from monocytes, whereas granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) trigger monocytic differentiation into DCs. However, regulatory mechanisms for the polarization of monocytic differentiation are still unclear. The present study was undertaken to clarify the mechanism of triggering the deflection of OC and DC differentiation from monocytes. GM-CSF and IL-4 abolished monocytic differentiation into OCs while inducing DC differentiation even in the presence of M-CSF and RANK ligand. GM-CSF and IL-4 in combination potently up-regulate tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) and activity in monocytes, causing ectodomain shedding of M-CSF receptor, resulting in the disruption of its phosphorylation by M-CSF as well as the induction of osteoclastogenesis from monocytes by M-CSF and RANK ligand. Interestingly, TACE inhibition robustly causes the resumption of the surface expression of M-CSF receptor on monocytes, facilitating M-CSF-mediated phosphorylation of M-CSF receptor and macrophage/OC differentiation while impairing GM-CSF- and IL-4-mediated DC differentiation from monocytes. These results reveal a novel proteolytic regulation of M-CSF receptor expression in monocytes to control M-CSF signaling and monocytic differentiation into macrophage/OC-lineage cells or DCs.
Wang H, Li Y, Li H, Yan X, Jiang Z, Feng L J Orthop Translat. 2025; 51:82-93.
PMID: 39991456 PMC: 11847249. DOI: 10.1016/j.jot.2024.12.004.
RECK as a Potential Crucial Molecule for the Targeted Treatment of Sepsis.
Qin Y, Liao S, Sun J, Ye H, Li J, Pan J J Inflamm Res. 2025; 18:1787-1813.
PMID: 39931174 PMC: 11809362. DOI: 10.2147/JIR.S501856.
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer.
Elorbany S, Berlato C, Carnevalli L, Maniati E, Barry S, Wang J Nat Commun. 2024; 15(1):10144.
PMID: 39578450 PMC: 11584700. DOI: 10.1038/s41467-024-54295-x.
Zhang S, Huang C, Li Y, Li Z, Zhu Y, Yang L Front Immunol. 2024; 15:1473145.
PMID: 39559350 PMC: 11570797. DOI: 10.3389/fimmu.2024.1473145.
Degavre C, Lepez A, Ibanez S, Francois C, Glowacka K, Guilbaud C J Immunother Cancer. 2024; 12(11).
PMID: 39500528 PMC: 11552574. DOI: 10.1136/jitc-2024-009752.